ATE166354T1 - Azabicycloarylacetylen- und arylenynoxine als cholinergische mittel und verfahren zur behandlung - Google Patents

Azabicycloarylacetylen- und arylenynoxine als cholinergische mittel und verfahren zur behandlung

Info

Publication number
ATE166354T1
ATE166354T1 AT92921974T AT92921974T ATE166354T1 AT E166354 T1 ATE166354 T1 AT E166354T1 AT 92921974 T AT92921974 T AT 92921974T AT 92921974 T AT92921974 T AT 92921974T AT E166354 T1 ATE166354 T1 AT E166354T1
Authority
AT
Austria
Prior art keywords
azabicycloarylacetylene
arylenynoxines
treatment
methods
azabicyclo
Prior art date
Application number
AT92921974T
Other languages
English (en)
Inventor
David Jeffrey Lauffer
Walter Hamilton Moos Moos
Michael Raymond Pavia
Haile Tecle
Anthony Jerome Thomas
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of ATE166354T1 publication Critical patent/ATE166354T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Carbon And Carbon Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
AT92921974T 1991-10-16 1992-10-09 Azabicycloarylacetylen- und arylenynoxine als cholinergische mittel und verfahren zur behandlung ATE166354T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/778,412 US5306718A (en) 1990-03-06 1991-10-16 Oxime and amine substituted azabicyclo and azocyclo muscarinic agonists and methods of treatment

Publications (1)

Publication Number Publication Date
ATE166354T1 true ATE166354T1 (de) 1998-06-15

Family

ID=25113261

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92921974T ATE166354T1 (de) 1991-10-16 1992-10-09 Azabicycloarylacetylen- und arylenynoxine als cholinergische mittel und verfahren zur behandlung

Country Status (17)

Country Link
US (2) US5306718A (de)
EP (1) EP0608336B1 (de)
JP (1) JP3367670B2 (de)
KR (1) KR100241479B1 (de)
AT (1) ATE166354T1 (de)
AU (1) AU658685B2 (de)
CA (1) CA2115443C (de)
DE (1) DE69225601T2 (de)
DK (1) DK0608336T3 (de)
ES (1) ES2119823T3 (de)
FI (1) FI106797B (de)
NO (1) NO302072B1 (de)
NZ (1) NZ244726A (de)
PH (1) PH31431A (de)
PT (1) PT100961B (de)
WO (1) WO1993008192A1 (de)
ZA (1) ZA927973B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5346911A (en) * 1990-03-06 1994-09-13 Warner-Lambert Company Azabicyclo and azacyclo oxime and amine cholinergic agents and methods of treatment
US5514812A (en) * 1994-06-10 1996-05-07 Warner-Lambert Company Preparation of stereochemically pure oximes with muscarinic activity
AUPM910994A0 (en) * 1994-10-28 1994-11-24 Commonwealth Scientific And Industrial Research Organisation Bisallyloxyimides
US5534522A (en) * 1995-06-07 1996-07-09 Warner-Lambert Company (R)-(Z)-1-azabicyclo [2.2.1] heptan-3-one,O-[3-(3-methoxyphenyl)-2-propynyl] oxime maleate as a pharmaceutical agent
US6168912B1 (en) 1996-01-23 2001-01-02 Martek Biosciences Corporation Method and kit for making a multidimensional combinatorial chemical library
US6121459A (en) * 1997-01-27 2000-09-19 Warner-Lambert Company Single pot process for producing (Z)-azabicyclo oxime ethers
US6924313B1 (en) 1999-09-23 2005-08-02 Pfizer Inc. Substituted tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
US6544974B2 (en) * 1999-09-23 2003-04-08 G.D. Searle & Co. (R)-chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesteryl ester transfer protein activity
CA2450073C (en) 2001-07-25 2017-08-29 Biomarin Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
KR100465277B1 (ko) * 2002-01-24 2005-01-13 한국과학기술연구원 신규한 옥심계 아자 두 고리 화합물 및 그 제조방법
EP2671508B1 (de) 2005-04-28 2020-09-16 Proteus Digital Health, Inc. Pharma-Informatiksystem
JP2010503710A (ja) 2006-09-18 2010-02-04 ラプトール ファーマシューティカル インコーポレイテッド 受容体関連タンパク質(rap)結合体の投与による肝障害の処置
ES2919563T3 (es) 2009-02-20 2022-07-27 Enhanx Biopharm Inc Sistema de administración de medicamentos a base de glutatión
KR20180114970A (ko) 2009-05-06 2018-10-19 라보라토리 스킨 케어, 인크. 활성제-칼슘 포스페이트 입자 복합체를 포함하는 피부 전달 조성물 및 이들을 이용하는 방법
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3479346A (en) * 1961-08-08 1969-11-18 Sterling Drug Inc N-acyl-n- (and n,n-bis-) ((1-piperidyl)-lower-alkyl)amines
US3502692A (en) * 1962-06-13 1970-03-24 American Cyanamid Co Cyclic nitroxides and process for preparing same
DE2019536A1 (de) * 1970-04-23 1971-11-11 Basf Ag Oximcarbamate
DE2552176A1 (de) * 1975-11-21 1977-06-02 Hoechst Ag Neue piperidin-derivate, ihre herstellung und verwendung
US4341795A (en) * 1975-12-01 1982-07-27 Union Carbide Corporation Asymmetrical bis-carbamate compounds
US4710508A (en) * 1986-12-08 1987-12-01 Warner-Lambert Company O-substituted tetrahydropyridine oxime cholinergic agents
NZ226000A (en) * 1987-09-10 1991-06-25 Merck Sharp & Dohme Oxadiazolyl-azabicycloheptanes and pharmaceutical compositions
US4937239A (en) * 1989-02-13 1990-06-26 Warner-Lambert Company Azabicycloalkane oxime & azabicycloalkene oxime muscarinic agents
IL97266A0 (en) * 1990-03-06 1992-05-25 Warner Lambert Co Azabicyclo and azacyclo oximes and amines,their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
PT100961B (pt) 1999-07-30
DE69225601T2 (de) 1998-12-17
NO941365D0 (no) 1994-04-15
FI106797B (fi) 2001-04-12
DE69225601D1 (de) 1998-06-25
US5306718A (en) 1994-04-26
DK0608336T3 (da) 1999-01-18
EP0608336A1 (de) 1994-08-03
ES2119823T3 (es) 1998-10-16
NZ244726A (en) 1995-09-26
AU2783592A (en) 1993-05-21
NO941365L (no) 1994-04-15
US5482938A (en) 1996-01-09
KR100241479B1 (ko) 2000-03-02
FI941699A0 (fi) 1994-04-13
CA2115443A1 (en) 1993-04-29
EP0608336B1 (de) 1998-05-20
AU658685B2 (en) 1995-04-27
CA2115443C (en) 2003-05-13
ZA927973B (en) 1994-04-15
JPH07500337A (ja) 1995-01-12
WO1993008192A1 (en) 1993-04-29
FI941699L (fi) 1994-04-13
NO302072B1 (no) 1998-01-19
PT100961A (pt) 1993-11-30
PH31431A (en) 1998-11-03
JP3367670B2 (ja) 2003-01-14

Similar Documents

Publication Publication Date Title
CA2037541A1 (en) Azabicyclo and azacyclo oxime and amine cholinergic agents and methods of treatment
DE69225601D1 (de) Azabicycloarylacetylen- und arylenynoxine als cholinergische mittel und verfahren zur behandlung
CO4810230A1 (es) Nuevos derivados del 19-nor-pregneno
RU95105988A (ru) Производные эфиров о-бензилоксимов, способ их получения и пестицидная композиция на их основе
DE69807115D1 (de) Angiostatische verbindungen und zusammensetzungen zur behandlung des glc1a glaukoms
ATE250031T1 (de) Tricyclische kondensierte heterocyclische verbindungen zur behandlung von seniler demenz
DE69427517D1 (de) Tetracyclische kondensierte heterocyclische Verbindungen zur Behandlung von seniler Demenz
ZA939476B (en) Inhibitors of hiv protease useful for the treatment of aids
TW333532B (en) Benzopyrans
ZA927924B (en) Azabicyclo oxime and amine cholinergic agents and methods of treatment
DE69725133D1 (de) Als entzündungshemmende mittel nützliche dihydrobenzofurane und verwandte verbindungen
ATE160566T1 (de) Amphotere tricyclische verbindungen als antihistaminische und antiallergische mittel
ATE224387T1 (de) N-(pyridinylamino)isoindoline und verwandte verbindungen
AP9901559A0 (en) Tricyclic 3-keto derivatives of 6-0-methylerythromycin.
DE69314413D1 (de) Piperidino-3,4-dihydrocarbostyryl Verbindungen zur Behandlung von ischämischen Störungen
DE69827706D1 (de) 5-(Heteroaryl)alkyl)-3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid (PBI) Derivate zur Behandlung von Störungen des zentralen Nervensystems
DE69333270D1 (de) Aminderivate von oxo- und hydroxy- substituierten kohlenwasserstoffen
DE69216479D1 (de) Verbindungen und Verfahren zur Behandlung thromboembolischer Störungen
EA200200574A1 (ru) НОВЫЕ ЦИКЛИЧЕСКИЕ α-АМИНО-γ-ГИДРОКСИАМИДНЫЕ СОЕДИНЕНИЯ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, ИХ СОДЕРЖАЩИЕ

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee